KeyCorp Weighs in on R1 RCM Inc.’s Q2 2021 Earnings (NASDAQ:RCM)


Share on StockTwits

R1 RCM Inc. (NASDAQ:RCM) – Investment analysts at KeyCorp dropped their Q2 2021 earnings estimates for shares of R1 RCM in a research note issued to investors on Tuesday, January 12th. KeyCorp analyst D. Hooker now anticipates that the healthcare provider will post earnings per share of $0.06 for the quarter, down from their previous forecast of $0.07. KeyCorp currently has a “Overweight” rating and a $26.00 price target on the stock.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Tuesday, November 3rd. The healthcare provider reported $0.11 earnings per share (EPS) for the quarter. R1 RCM had a net margin of 4.02% and a return on equity of 182.08%. The firm had revenue of $307.20 million for the quarter, compared to the consensus estimate of $295.38 million. During the same period last year, the firm earned $0.01 earnings per share. The company’s quarterly revenue was up 2.0% on a year-over-year basis.

Several other brokerages also recently weighed in on RCM. Royal Bank of Canada raised their target price on R1 RCM from $20.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, December 9th. ValuEngine lowered R1 RCM from a “buy” rating to a “hold” rating in a report on Tuesday, December 1st. Zacks Investment Research cut shares of R1 RCM from a “hold” rating to a “strong sell” rating in a research report on Friday, January 8th. Cantor Fitzgerald raised their price target on R1 RCM from $18.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, November 4th. Finally, SVB Leerink boosted their price objective on R1 RCM from $22.00 to $26.00 and gave the stock an “outperform” rating in a research note on Thursday, December 3rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. R1 RCM currently has a consensus rating of “Buy” and an average price target of $22.40.

NASDAQ:RCM opened at $25.37 on Thursday. The stock has a market cap of $2.96 billion, a PE ratio of 253.73, a price-to-earnings-growth ratio of 20.19 and a beta of 0.57. R1 RCM has a fifty-two week low of $7.12 and a fifty-two week high of $25.60. The firm’s fifty day simple moving average is $22.61 and its 200-day simple moving average is $17.55. The company has a quick ratio of 1.27, a current ratio of 1.27 and a debt-to-equity ratio of 12.08.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC boosted its position in shares of R1 RCM by 87.3% during the third quarter. Cubist Systematic Strategies LLC now owns 116,720 shares of the healthcare provider’s stock worth $2,002,000 after buying an additional 54,387 shares during the period. Sei Investments Co. grew its holdings in R1 RCM by 138.5% during the 3rd quarter. Sei Investments Co. now owns 101,471 shares of the healthcare provider’s stock valued at $1,740,000 after purchasing an additional 58,927 shares in the last quarter. BlackRock Inc. lifted its position in R1 RCM by 109.4% in the 3rd quarter. BlackRock Inc. now owns 16,718,057 shares of the healthcare provider’s stock valued at $286,714,000 after purchasing an additional 8,734,205 shares during the last quarter. Great West Life Assurance Co. Can lifted its position in R1 RCM by 529.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 37,557 shares of the healthcare provider’s stock valued at $1,491,000 after purchasing an additional 31,595 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its position in R1 RCM by 24.3% in the 3rd quarter. Allianz Asset Management GmbH now owns 482,121 shares of the healthcare provider’s stock valued at $8,269,000 after purchasing an additional 94,208 shares during the last quarter.

About R1 RCM

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

Recommended Story: Green Investing

Earnings History and Estimates for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.